An inhalation model of airway allergic response to inhalation of environmental Aspergillus fumigatus conidia in sensitized BALB/c mice

Medical Mycology

Volumn 48, Issue 8, 2010, Pages 1056-1065

  Hoselton, Scott A ^a   Samarasinghe, Amali E ^a   Seydel, Jena M ^a   Schuh, Jane M ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

allergy; aspergillus; asthma; fungi; murine model

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; FUNGAL EXTRACT; FUNGUS ANTIGEN;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; BRONCHUS HYPERREACTIVITY; CONIDIUM; ENVIRONMENTAL EXPOSURE; EXPOSURE; FIBROSIS; FUNGAL SENSITIZATION; FUNGUS CULTURE; GOBLET CELL; IMMUNIZATION; INOCULATION; MOUSE; MUSCLE MASS; NONHUMAN; SENSITIZATION; SIMULATION;

ANIMALS; ANTIGENS, FUNGAL; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; INHALATION; MICE; MICE, INBRED BALB C; SPORES, FUNGAL;

ANIMALIA; ASPERGILLUS; ASPERGILLUS FUMIGATUS; FUNGI; MURINAE; MUS;

EID: 78449236015     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.485582     Document Type: Article

References (40)

1. World Health Organization. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. Geneva: World Health Organization, 2007.
2. Denning DW, O ' Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27: 615-626.
3. Denning DW, O ' Driscoll BR, Powell G, et al . Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the fungal asthma sensitization trial (fast) study. Am J Respir Crit Care Med 2009; 179: 11-18.
4. Portnoy JM, Barnes CS, Kennedy K. Importance of mold allergy in asthma. Curr Allergy Asthma Rep 2008; 8: 71-78.
5. Schwindt CD, Tjoa T, Floro JN, McLaren C, Delf no RJ. Association of atopy to asthma severity and medication use in children. J Asthma 2006; 43: 439-446.
6. O' Driscoll BR, Hopkinson LC, Denning DW. Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulm Med 2005; 5: 4.
7. Hogaboam CM, Blease K, Mehrad B, et al . Chronic airway hyperreactivity, goblet cell hyperplasia, and peribronchial f brosis during allergic airway disease induced by Aspergillus fumigatus. Am J Pathol 2000; 156: 723-732.
8. Haczku A, Atochina EN, Tomer Y, et al. Aspergillus fumigatus-induced allergic airway inf ammation alters surfactant homeostasis and lung function in balb/c mice. Am J Respir Cell Mol Biol 2001; 25: 45-50.
9. Singh SP, Barrett EG, Kalra R, et al . Prenatal cigarette smoke decreases lung camp and increases airway hyperresponsiveness. Am J Respir Crit Care Med 2003; 168: 342-347.
10. Corry DB, Grunig G, Hadeiba H, et al . Requirements for allergen-induced airway hyperreactivity in T and B cell-def cient mice. Mol Med 1998; 4: 344-355.
11. Dague E, Alsteens D, Latge JP, Dufrene YF. High-resolution cell surface dynamics of germinating Aspergillus fumigatus conidia. Biophys J 2008; 94: 656-660.
12. Hohl TM, Van Epps HL, Rivera A, et al. Aspergillus fumigatus triggers inf ammatory responses by stage-specif c beta-glucan display. PLoS Pathog 2005; 1: e30.
13. Ochs M, Nyengaard JR, Jung A, et al . The number of alveoli in the human lung. Am J Respir Crit Care Med 2004; 169: 120-124.
14. Piggott WR, Emmons CW Device for inhalation exposure of animals to spores. Proc Soc Exp Biol Med 1960; 103: 805-806.
15. Sidransky H, Friedman L. The effect of cortisone and antibiotic agents on experimental pulmonary aspergillosis. Am J Pathol 1959; 35:169-183.
16. Burrell R. Improved device for the administration of fungal spores to small animals via the respiratory route. Appl Microbiol 1970; 20: 984-985.
17. Rivera A, Van Epps HL, Hohl TM, Rizzuto G, Pamer EG. Distinct cd4+-t-cell responses to live and heat-inactivated aspergillus fumigatus conidia. Infect Immun 2005; 73: 7170-7179.
18. Busse W, Banks-Schlegel S, Noel P, et al . Future research directions in asthma: an NHLBI working group report. Am J Respir Crit Care Med 2004; 170: 683-690.
19. Xiong L, Fang ZY, Tao XN, Bai M, Feng G. Effect and mechanism of ligustrazine on Th1/Th2 cytokines in a rat asthma model. Am J Chin Med 2007; 35: 1011-1020.
20. Anthoni M, Wang G, Leino MS, et al . Smad3-signaling and Th2 cytokines in normal mouse airways and in a mouse model of asthma. Int J Biol Sci 2007; 3: 477-485.
21. Holt PG, Sly PD. Th2 cytokines in the asthma late-phase response. Lancet 2007; 370: 1396-1398.
22. Jaffar Z, Ferrini ME, Buford MC, Fitzgerald GA, Roberts K. Prostaglandin I2-IP signaling blocks allergic pulmonary inf ammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma. J Immunol 2007; 179: 6193-6203.
23. Nagata Y, Kamijuku H, Taniguchi M, Ziegler S, Seino K. Differential role of thymic stromal lymphopoietin in the induction of airway hyperreactivity and Th2 immune response in antigen-induced asthma with respect to natural killer T cell function. Int Arch Allergy Immunol 2007; 144: 305-314.
24. Lee JS, Lee CM, Jeong YI, et al . D-pinitol regulates Th1/Th2 balance via suppressing Th2 immune response in ovalbumin-induced asthma. FEBS Lett 2007; 581: 57-64.
25. Jacobsen EA, Ochkur SI, Pero RS, et al . Allergic pulmonary inf ammation in mice is dependent on eosinophil-induced recruitment of effector T cells. J Exp Med 2008; 205: 699-710.
26. Jacobsen EA, Taranova AG, Lee NA, Lee JJ. Eosinophils: singularly destructive effector cells or purveyors of immunoregulation? J Allergy Clin Immunol 2007; 119: 1313-1320.
27. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inf ammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-1745.
28. Bousquet J, Vignola AM, Chanez P, et al. Airways remodeling in asthma: no doubt, no more? Int Arch Allergy Immunol 1995; 107: 211-214.
29. Busse W, Elias J, Sheppard D, Banks-Schlegel S. Airway remodeling and repair. Am J Respir Crit Care Med 1999; 160: 1035-1042.
30. Tran MU, Weir AJ, Fanucchi MV, et al . Smooth muscle hypertrophy in distal airways of sensitized infant rhesus monkeys exposed to house dust mite allergen. Clin Exp Allergy 2004; 34: 1627-1633.
31. Woodruff PG, Dolganov GM, Ferrando RE, et al . Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med 2004; 169: 1001-1006.
32. Fauchet F, Jadoul M, Franssen JD, Zhang J, De Groote D. Characterization of monoclonal antibodies against human interleukin-12 and their use in an ELISA for the measurement of this cytokine. Ann NY Acad Sci 1996; 795: 334-336.
33. Hu CY, Rodriguez-Pinto D, Du W, et al . Treatment with CD20-specif c antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117: 3857-3867.
34. Kurup VP, Mauze S, Choi H, Seymour BW, Coffman RL. A mu-rine model of allergic bronchopulmonary aspergillosis with elevated eosinophils and IgE. J Immunol 1992; 148: 3783-3788.
35. Grunig G, Corry DB, Leach MW, et al . Interleukin-10 is a natural suppressor of cytokine production and inf ammation in a murine model of allergic bronchopulmonary aspergillosis. J Exp Med 1997; 185: 1089-1099.
36. Wang JM, Denis M, Fournier M, Laviolette M. Experimental allergic bronchopulmonary aspergillosis in the mouse: immunological and histological features. Scand J Immunol 1994; 39: 19-26.
37. Koth LL, Rodriguez MW, Bernstein XL, et al. Aspergillus antigen induces robust Th2 cytokine production, inf ammation, airway hyperreactivity and f brosis in the absence of MCP-1 or CCR2. Respir Res 2004; 5: 12.
38. Kheradmand F, Kiss A, Xu J, et al . A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J Immunol 2002; 169: 5904-5911.
39. Cenci E, Mencacci A, Del Sero G, et al . Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999; 180:1957-1968.
40. Van Epps HL, Feldmesser M, Pamer EG. Voriconazole inhibits fungal growth without impairing antigen presentation or T-cell activation. Antimicrob Agents Chemother 2003; 47: 1818-1823.